Cimeio Therapeutics
  • Home
  • About Us
  • Careers
  • News
  • Contact Us
Select Page

Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH

by admin | Dec 11, 2022 | Press Release

Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH –Preclinical data for Cimeio’s CD117- and CD123-shielded cells, and CD117 mAbs, demonstrate the potential of Cimeio’s SCIP platform to enable novel immunotherapy-based conditioning and...

Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform

by admin | Nov 28, 2022 | Press Release

Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform Basel, Switzerland and Cambridge, MA, November 28, 2022 Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent...

Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline

by admin | Nov 3, 2022 | Press Release

Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline –Company also strengthens Board of Directors with appointments of Luca Santarelli and Michael Tomsicek– Basel, Switzerland and Cambridge, MA, November 3, 2022 Cimeio Therapeutics,...

Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A

by admin | Apr 13, 2022 | Press Release

Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A — Novel cell therapy company launched out of Versant’s Ridgeline Discovery Engine —- Cimeio developing Shielded-Cell & Immunotherapy Pairs aimed at revolutionizing cell...

Recent Posts

  • Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH
  • Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform
  • Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline
  • Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A

Recent Comments

No comments to show.
Cimeio Therapeutics Logo

Transforming Hematopoietic Stem Cell Transplant and Adoptive Cell Therapies


Cimeio Therapeutics, Inc.
1 Broadway, 14th floor
Cambridge, MA 02142
USA


+41 61 225 46 00

Sitemap

  • Home
  • About Us
  • Careers
  • News
  • Contact Us

© 2022 Cimeio Therapeutics AG

  • Follow
Contact Us
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}